Madhan Masilamani

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 3

Top Topics

Acute Lymphoblastic Leukemia

Top Venues

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Brian Kiesel, Mayu Osawa, Madhan Masilamani, Merav Bar, Kevin Hsu, Colin Godwin, Michael Burgess, Manisha Lamba, Allison Gaudy
Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response Analysis. Clinical pharmacology and therapeutics (2024)
Brian Kiesel, Mayu Osawa, Madhan Masilamani, Merav Bar, Kevin Hsu, Colin Godwin, Michael Burgess, Manisha Lamba, Allison Gaudy
Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response Analysis. Clinical pharmacology and therapeutics 116 (3) (2024)
Madhan Masilamani, Vibha Jawa, Yanshan Dai, Romita Das, Alice Park, Manisha Lamba, Fan Wu, Xirong Zheng, Edwin Lu, Carol Gleason, Tim Mack, Johanna Mora, Sekhar Surapaneni
Bioanalytical Methods for Characterization of CAR-T Cellular Kinetics: Comparison of PCR Assays and Matrices. Clinical pharmacology and therapeutics (2023)